Published March 10, 2025
| Version v4
Dataset
Open
CAPN2: A Target Enabling Package
Authors/Creators
- 1. University of North Carolina, Chapel Hill, NC, USA
- 2. Queen's University, Ontario, Canada
- 3. Alzheimer's Research UK Oxford Drug Discovery Institute, Centre for Medicines Discovery, University of Oxford, Oxford, United Kingdom
- 4. Emory University, Atlanta, GA 30322, USA
Description
CAPN2 mediates neurodegenerative effect through cleavage of a range of proteins linked to tau hyperphosphorylation (GSK-3β), higher levels of Aβ (NCX3), or poor memory (CPEB3). Inhibiting calpain-2 might reduce cleavage of these proteins and reverse its neurodegenerative effect. This aim of this TEP is to produce reagents to allow for further analysis of CAPN2 as a potential target for AD treatment.
Notes
This document is version 1 of the CAPN2 TEP.
Files
TREAT-AD Basic TEP_CAPN2_v3.1.pdf
Files
(2.7 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:476bc296bc54bc277e895fd928b5c579
|
2.7 MB | Preview Download |